This is the authors' abstract. We don't add key points for this paper.
Nucleic acid-based therapeutics (NBTs) are an emerging class of drugs with potential for the treatment of a wide range of central nervous system conditions. To date, pertaining to CNS indications, there are two commercially available NBTs and a large number of ongoing clinical trials. However, these NBTs are applied directly to the brain due to very low blood brain barrier permeability. In this review, we outline recent advances in chemical modifications of NBTs and NBT delivery techniques intended to promote brain exposure, efficacy, and possible future systemic application.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
McCartan et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: